Community-based approaches to HIV treatment in resource-poor settings

Lancet

Volumn 358, Issue 9279, 2001, Pages 404-409

  Farmer, Paul ^a   Léandre, Fernet ^b   Mukherjee, Joia S ^a   Claude, Marie Sidonise ^b   Nevil, Patrice ^b   Smith Fawzi, Mary C ^a   Koenig, Serena P ^a   Castro, Arachu ^a   Becerra, Mercedes C ^a   Sachs, Jeffrey ^c   Attaran, Amir ^c   Kim, Jim Yong ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Centre Thomas J White   (Haïti)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMYCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CASE REPORT; CLINICAL FEATURE; COMMUNITY CARE; DEVELOPING COUNTRY; DISEASE COURSE; DRUG COST; FEMALE; HEALTH AUXILIARY; HEALTH CARE AVAILABILITY; HEALTH CARE PERSONNEL; HEALTH ECONOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION PREVENTION; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 0035806721     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)05550-7     Document Type: Note

References (43)

1. Of epidemic proportions/ UN report: AIDS deaths to surpass plague, Spanish flu
2. The changing face of AIDS: Implications for policy and practice
3. Changing patterns of mortality across Europe in patients with human immunodeficiency virus infection
4. Natural history of HIV infection in the era of combination antiretroviral therapy
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. Advances in control of sexually transmitted diseases in developing countries
7. Prevention without treatment is not sustainable
8. A prospective study of HIV-seropositive asymptomatic women of childbearing age in a developing country
9. Ethnography, social analysis, and the prevention of sexually transmitted HIV infection
10. Condoms, coups, and the ideology of prevention: Facing failure in rural Haiti
11. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
12. Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV
13. Letter from Haiti
14. Costs of HIV medical care in the era of highly active antiretroviral therapy
15. Weight loss as a predictor of survival and disease progression in HIV infection
16. Clinical factors associated with weight loss related to infection with human immunodeficiency virus in the multicenter AIDS cohort study
17. Multivariate models for predicting progression to AIDS and survival in human immunodeficiency virus-infected persons
18. Association between immune activation, changes of iron metabolism and anaemia in patients with HIV infection
19. Frequencies of opportunistic diseases prior to death among HIV-infected persons. Community Program for Clinical Research on AIDS
20. Access to essential drugs in poor countries: A lost battle?
21. Selling cheap 'generic' drugs, India's copycats irk industry
22. Assessment of worldwide tuberculosis control
23. When tuberculosis treatment fails: A social behavioral account of patient adherence
24. Tuberculosis, poverty, and 'compliance': Lessons from rural Haiti
25. The clinical management of multidrug-resistant tuberculosis
26. Community-based approaches to the control of multidrug-resistant tuberculosis: Introducing 'DOTS-Plus'
27. Responding to outbreaks of multidrug-resistant tuberculosis: introducing 'DOTS-Plus
28. Procurement ofsecond-line anti-tuberculosis drugs for DOTS-Plus pilot projects
29. Viral load and heterosexual transmission of human immunodeficiency virus type 1
30. Rifampicin or ethambutol in the routine treatment of tuberculosis
31. The dilemma of MDRTB in the global era
32. An unusual calculus of life and death; as millions perished in pandemic, firms debated access to drugs; players in the debate over drug availability and pricing
33. The cost effectiveness of combination antiretroviral therapy for HIV disease
34. Advances in cost-effectiveness analysis of health interventions